Neuroblastoma trials in Germany

In Germany 10 Also abroad 128

10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Where
Berlin
Age
18 months to 18 years
People
144 worldwide
Run by
Renaissance Pharma Ltd.
See details and how to joinNCT07549321 · EU 2025-524397-42-00
Phase 1Not yet taking people in Germany
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Where
Münster
Age
1 year to 25 years
People
30
Run by
Universität Münster
See details and how to joinNCT07897968
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Berlin, Cologne, Giessen, Muenster, Tuebingen
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 3Not yet taking people in Germany
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Cologne, Dortmund, Dresden, Erfurt, Erlangen, Giessen, Goettingen, Halle (Saale), Jena, Karlsruhe, Kassel, Krefeld, Leipzig, Magdeburg, Mainz, Mannheim, Muenster, Regensburg, Sankt Augustin, Stuttgart, Wuerzburg
Age
Up to 64 years
People
231
Run by
University Of Cologne
See details and how to join2024-517295-37-00 · EU 2024-517295-37-00
Phase 1Taking people
Long-term follow-up of patients treated with GD2IL18CART
Where
Erlangen, Essen, Muenster, Tuebingen
People
20
Run by
Universitaet Muenster
See details and how to join2025-521497-34-00 · EU 2025-521497-34-00
Phase 1Taking people
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Where
Erlangen, Essen, Muenster, Tuebingen
People
48
Run by
Universitaet Muenster
See details and how to join2022-501725-21-00 · EU 2022-501725-21-00
Phase 1/2Taking people
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
Where
Berlin, Essen, Frankfurt Am Main, Hamburg, Muenster
Age
Up to 64 years
People
72 worldwide
Run by
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504880-18-00 · EU 2023-504880-18-00
Phase 1/2Taking people
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Where
Augsburg, Berlin, Essen, Greifswald, Hamburg, Köln, Mainz, München, Münster, Regensburg, Tübingen
Age
1 year to 64 years
People
160 worldwide
Run by
University of Birmingham
See details and how to joinNCT07334301 · EU 2024-516115-24-00
Phase 1Taking people
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
Where
Berlin, Cologne, Greifswald, Tuebingen
Age
18 months to 18 years
People
38 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06485947 · EU 2023-509673-22-00
Phase 3Taking people
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Dortmund, Dresden, Düsseldorf, Erfurt, Erlangen, Essen, Frankfurt, Giessen, Göttingen, Greifswald, Halle Saale, Hamburg, Hanover, Heidelberg, Homburg, Jena, Karlsruhe, Kassel, Kiel, Köln, Krefeld, Leipzig, Luebeck, Magdeburg, Mainz, München, Münster, Regensburg, Rostock, Stuttgart, Tübingen, Ulm, Würzburg, UNIVERSITÄTSKLINIKUM FREIBURG
Age
Up to 21 years
People
800 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT04221035 · EU 2024-514917-36-00